Skip to main content
OpenTrials

Clinical trial condition

Depressive Disorder, Major

Explore clinical trials studying Depressive Disorder, Major. Study availability and eligibility vary by location and protocol.

285 public trials 32 recruiting studies
Refine in advanced search Browse all conditions

Depressive Disorder, Major trial results

Completed

A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine

NCT06280235

Conditions
Depressive Disorder, Depressive Disorder, Major, Mental Disorders, +1 more
Locations
  • Southwest Biomedical Research, LLC Tucson, Arizona, United States
  • Excell Research Inc. Oceanside, California, United States
  • NRC Research Institute Orange, California, United States
  • Asclepes Research Centers-Panorama City-62905 Panorama City, California, United States
View all 52 locations
View Trial Details
Completed

A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

NCT05550532

Conditions
Anhedonia, Depressive Disorder, Depressive Disorder, Major, +7 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Sunwise Clinical Research Lafayette, California, United States
  • Pacific Neuropsychiatric Specialists Orange, California, United States
  • Prospective Research Innovations Inc Rancho Cucamonga, California, United States
View all 131 locations
View Trial Details
Completed

Olfactory Training and Emotional State

NCT03605524

Conditions
Anosmia, Behavior, Behavioral Symptoms, +12 more
Locations
  • University health service, University ,Tours Tours, France
  • UMR 1253 IBrain, University, Tours Tours, France
  • University Psychiatric Clinic, University hospital,Tours Tours, France
View Trial Details
Completed

A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

NCT05455684

Conditions
Anhedonia, Depressive Disorder, Depressive Disorder, Major, +7 more
Locations
  • SW Biomedical Research LLC Tucson, Arizona, United States
  • University of Arizona Tucson, Arizona, United States
  • Advanced Research Center Inc Anaheim, California, United States
  • Proscience Research Group Culver City, California, United States
View all 120 locations
View Trial Details
Completed

A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment

NCT04829318

Conditions
Depressive Disorder, Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant, +2 more
Locations
  • FunDaMos Buenos Aires, Argentina
  • CEN Consultorios Especializados en Neurociencias Córdoba, Argentina
  • Fundacion Lennox Córdoba, Argentina
  • Instituto Medico DAMIC Córdoba, Argentina
View all 59 locations
View Trial Details
Completed

A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

NCT04513912

Conditions
Depressive Disorder, Depressive Disorder, Major, Mental Disorders, +1 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • SW Biomedical Research LLC Tucson, Arizona, United States
  • Proscience Research Group Culver City, California, United States
  • Pharmacology Research Institute Encino, California, United States
View all 175 locations
View Trial Details
Completed

54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

NCT03039192

Conditions
Depressive Disorder, Depressive Disorder, Major, Mental Disorders, +1 more
Locations
  • UAB Department of Psychiatry and Behavioral Neurobiology Birmingham, Alabama, United States
  • Metropolitan Neuro Behavioral Institute Chandler, Arizona, United States
  • Collaborative NeuroScience Network Garden Grove, California, United States
  • Yale University New Haven, Connecticut, United States
View all 56 locations
View Trial Details
Completed

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

NCT03185819

Conditions
Depressive Disorder, Depressive Disorder, Major, Mental Disorders, +1 more
Locations
  • Institute of Living/ Hartford Hospital Hartford, Connecticut, United States
  • Yale University New Haven, Connecticut, United States
  • Atlanta Behavioral Research, LLC Atlanta, Georgia, United States
  • Rush University Medical Center Chicago, Illinois, United States
View all 51 locations
View Trial Details

Related conditions